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ABSTRACT Measuring CD4 counts remains an important component of HIV care.
The Visitect CD4 is the ﬁrst instrument-free low-cost point-of-care CD4 test with re-
sults interpreted visually after 40 min, providing a result of 350 CD4 cells/mm3.
The ﬁeld performance and diagnostic accuracy of the test was assessed among HIV-
infected pregnant women in South Africa. A nurse performed testing at the point-of-
care using both venous and ﬁnger-prick blood, and a counselor and laboratory staff
tested venous blood in the clinic laboratory (four Visitect CD4 tests/participant). Per-
formance was compared to the mean CD4 count from duplicate ﬂow cytometry
tests on venous blood (FACSCalibur Trucount). In 2017, 156 patients were enrolled,
providing a total of 624 Visitect CD4 tests (468 venous and 156 ﬁnger-prick sam-
ples). Of 624 tests, 28 (4.5%) were inconclusive. Generalized linear mixed modeling
showed better performance of the test on venous blood (sensitivity  81.7%; 95%
conﬁdence interval [CI] 72.3 to 91.1]; speciﬁcity  82.6%, 95% CI  77.1 to 88.1)
than on ﬁnger-prick specimens (sensitivity  60.7%; 95% CI  45.0 to 76.3; speciﬁc-
ity  89.5%, 95% CI  83.2 to 95.8; P 0.001). No difference in performance was
detected by cadre of health worker (P 0.113) or between point-of-care versus
laboratory-based testing (P 0.108). Adequate performance of Visitect CD4 with dif-
ferent operators and at the point of care, with no need of electricity or instrument,
shows the potential utility of this device, especially for facilitating decentralization of
CD4 testing services in rural areas.
KEYWORDS CD4 count, ﬁeld performance, HIV, South Africa, diagnostic accuracy,
point-of-care diagnostics, sensitivity, speciﬁcity, task shifting
Since the earliest days of HIV treatment and care, measuring CD4 cell counts hasbeen an important component of the continuum of care for adults and children
living with HIV. The CD4 count is an accurate predictor of disease status and immediate
risk of death and, as such, CD4 count testing at baseline for all people living with HIV
remains recommended (1, 2). CD4 testing continues to be used to assess eligibility for
elements of a package of care, including tracking disease progression, monitoring the
effectiveness of antiretroviral treatment (ART), adapting adherence support, antimicro-
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bial prophylaxis and preemptive treatment, screening for opportunistic infections, and
vaccination management, as well as ART prioritization (2, 3).
Recommendations for ART initiation based on the CD4 level have evolved over time,
with World Health Organization (WHO) guidelines arguing for a move to 350 cells/mm3
in 2010, a move to 500 cells/mm3 in 2013 (4, 5), and then the removal of the threshold
altogether in 2015 (6). Regardless of the epidemic proﬁle and disease burden, patients
with a CD4 count below 350 cells/mm3 should be prioritized for ART and care (7). This
group is at high risk of mortality, opportunistic infections, and cancers related to HIV.
CD4 count level is therefore still used for prioritizing ART and fast-tracking patients with
more advanced disease (2, 8).
Where ART is not immediately initiated, CD4 cell count assessments are recom-
mended every 6 to 12 months (7). In settings where viral load testing is not routinely
available (around half of ART patients worldwide), the WHO recommends that a CD4
count, in conjunction with clinical monitoring, should be used to diagnose treatment
failure (3). Moreover, patients with unstable or advanced HIV disease require ongoing
CD4 monitoring, regardless of whether viral load testing is available (2, 6).
Despite wide variability and poor precision of CD4 count assessments (9–11), ﬂow
cytometric methods have provided the gold standard for CD4 monitoring. These assays
require an electronic instrument, typically with constant power or batteries, and regular
equipment maintenance, as well as highly trained technicians and cold-chain manage-
ment of reagents (12, 13). Such requirements have restricted access to testing for
patients distant from central laboratories or well-established clinics. Availability of
point-of-care CD4 tests such as the Alere Pima CD4 has facilitated immediate decision-
making, patient management, and referral and improved patient care and retention in
some settings (14). Although performance of point-of-care CD4 technologies has been
acceptable (9, 15), implementation challenges remained due to the need for powered
instrumentation, device failures, maintenance requirements, and operator errors (15).
The Burnet Institute (Melbourne, Australia) has developed a low-cost (ca. $6.00 [U.S.
currency]/test) disposable instrument-free point-of-care CD4 test (Visitect CD4; licensed
to Omega Diagnostics, United Kingdom). The test is based on a lateral ﬂow principle,
detecting the amount of T-cell-associated CD4 antigen, and gives visual semiquantita-
tive results (above or below 350 CD4 cells/mm3) after 40 min. We sought to assess here
the ﬁeld performance and diagnostic accuracy of the Visitect CD4 test as performed by
different health worker cadres among HIV-infected pregnant women.
MATERIALS AND METHODS
Study design. This prospective diagnostic accuracy study with cross-sectional design is reported
according to the STARD Statement for Reporting Studies of Diagnostic Accuracy (16). Performance of the
Visitect CD4 was assessed using venous and ﬁnger-prick blood and performed by a variety of intended
users either at the clinical laboratory or at the point of care.
Participants. Pregnant women living with HIV aged 18 years and older and who were attending
antenatal services at Rahima Moosa Mother and Child Hospital in Johannesburg were recruited consec-
utively and invited to participate. To be eligible, women needed to have conﬁrmed HIV infection, as
documented by two separate HIV rapid antibody tests, and provide written informed consent. Women
received only the result of the ﬂow cytometry test.
Study procedures. Participants completed a brief questionnaire on sociodemographic characteris-
tics, gestational age, and health-seeking variables. Two types of blood samples were obtained from
patients in the antenatal clinic: a ﬁnger-prick specimen taken by the nurse and a venous blood sample
(in two 5-ml EDTA tubes) obtained by a phlebotomist.
CD4 testing. Six CD4 tests were performed in parallel: (i) Visitect CD4 from ﬁnger-prick blood by a
nurse at the point of care (one test); (ii) Visitect CD4 from venous blood by a nurse at the point of care
(one test); (iii) Visitect CD4 from venous blood at the clinic laboratory (two tests, performed by a
counselor, laboratory technologist, or other trained health worker); and (iv) a ﬂow cytometric CD4 cell
count from venous blood at the reference laboratory (two tests). All EDTA blood specimens were
analyzed within 12 h of venipuncture. Operators and readers of the tests were blinded to the results of
other tests and the clinical status of patients (aside from HIV status).
Reference test. The ﬂow cytometry reference tests were performed with the same venous sample
used in the clinic laboratory and tested on the same day by qualiﬁed laboratory personnel at
BioAnalytical Research Corporation (BARC), a SANAS-accredited research laboratory in Johannesburg,
South Africa, using a BD FACSCalibur Trucount ﬂow cytometry machine (Becton Dickinson, San Jose, CA).
A regular external quality assurance (EQA) program was performed on the reference test equipment
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through the UK National EQA Service. The mean value between the two ﬂow cytometry measurements
was taken as the reference value.
Visitect CD4 test. Visitect CD4 test kits contain a disposable test device, a 30-l micropipette for
ﬁnger-prick blood collection, one bottle of buffer, a sterile alcohol swab, and a safety lancet. Additional
materials required to run the test include disposable gloves, a timer, and equipment for the safe disposal
of used lancets. The Visitect CD4 test was performed according to the test procedure outlined in Fig. 1.
Finger-prick blood was obtained using the provided safety lancets, 30 l of blood was then collected in
the micropipette and added to well A. Venous blood was collected according to standard hospital
procedures using EDTA blood tubes. These were opened at point of care, and 30 l was removed using
a Gilson pipette and similarly added to well A. At 3 min after the addition of the blood sample to the test
device, one drop of running buffer was added to well A. After a 17-min wait, three drops of buffer were
added to well B. The test result was then read visually after another 20 min, and no more than 25 min
(i.e., no more than 45 min after test commencement). Tests read after this time were categorized as
inconclusive.
The Visitect CD4 test is a semiquantitative test with results classiﬁed as either 350 cells/mm3 or
350 cells/mm3. Tests results are visually interpreted by comparing the intensity of the test line with the
reference line: if the test line is darker than the reference line, the result is 350 cells/mm3; if the test
line is lighter than the reference line, then the result is 350 cells/mm3. Invalid tests without a control
line present were also considered inconclusive.
The ﬁrst of the two Visitect CD4 tests performed on venous blood in the clinic laboratory was read
twice visually by independent operators; all other tests were read once by the respective operator. All
four Visitect CD4 tests performed for each study participant were also scanned using an Axxin AX-2
reader to provide a permanent record of the test results, but only visually interpreted data were used for
analysis. Visitect CD4 tests used came from one of eight manufactured pilot batches; these were
manufactured with the same raw material speciﬁcations and using manufacturing process similar to that
used for the ﬁnal product which gained CE marking in November 2017. The used tests had an expiration
date approximately 1 month after the last participant was assessed.
Visitect CD4 training. Study staff and Visitect CD4 operators, including nurses, counselors, one
phlebotomist, and one laboratory technician, initially attended a 3-day training (total, 10 h) in prepara-
tion for an earlier beta testing study of 68 participants (data not shown). The training covered study
FIG 1 Timing and procedures for each step of the Visitect CD4 test.
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objectives and design, study procedures, recruitment, consent, conﬁdentiality, and the logistics of
implementation. Training days 2 and 3 were conducted by two staff from Omega Diagnostics, focused
on developing the knowledge and skills to accurately perform the Visitect CD4 test, and included
collection of ﬁnger-prick blood samples, the transfer of blood using micropipettes, the correct applica-
tion of buffer, and visual interpretation of the test results. Before commencement of this study, an
additional 2-day refresher training (5 h) and supervision of the testing took place in early 2017, led by
Omega Diagnostics. Training focused largely on the test procedures and data collection processes and
included several one-on-one sessions and supervision of the tests. A Proﬁciency Testing Guide was used
to facilitate and standardize competency assessment. Role plays were used to ensure understanding of
the informed consent and questionnaire administration procedures.
Data management and analysis. Study data were collected and managed using REDCap (research
electronic data capture) electronic data capture tools hosted at the University of the Witwatersrand,
which is a secure, password-protected, web-based application designed to support data capture for
research studies (17). All data were entered once, and each entry was checked for accuracy and was only
available to staff directly involved in data entry or analysis.
Data were obtained on patient ages, gestational ages, whether the patients were receiving ART, and
out-of-pocket costs to participants associated with that particular visit, which included transport to and
from the clinic, as well as incidental costs such as childcare. Data were also collected on the time taken
from phlebotomy/ﬁnger-prick to testing and the time taken between steps for each of the Visitect CD4
tests.
Pooled performance (sensitivity, speciﬁcity, positive predictive values [PPV], and negative predictive
values [NPV]) results are presented separately for venous and ﬁnger-prick samples according to STARD
guidelines (16). Moreover, the pooled performance of valid Visitect CD4 tests (i.e., excluding invalid
Visitect CD4 tests and Visitect CD4 tests that were not performed according to the testing protocol) with
conclusive reference tests, which were performed by either a nurse, counselor, or laboratory staff, was
examined using generalized linear mixed modeling (GLMM; generalized through logit link function and
binomial distribution). For sensitivity and speciﬁcity estimation, GLMM was used given the dependency
in test data (i.e., a single sample was tested separately by different operators) where study participant
positivity on the Visitect CD4 test was treated as a random effect, and ﬁxed terms for the reference test,
operator, blood sample type, and their interactions were also estimated to explore the extent to which
these factors moderate test performance. Nested likelihood ratio tests were used to provide inference in
comparing unadjusted and unconstrained models (i.e., exploration of the differential performance across
blood sample types and operators), and Bonferroni-corrected postestimation linear-equation Wald tests
were used to provide inference for further post hoc comparison across operator levels. Marginal
probabilities integrated over the estimated distribution of the random effect (18), and 95% conﬁdence
intervals (CI) from GLMM were produced to estimate the sensitivity and speciﬁcity for respective models.
For PPV and NPV estimation, marginal probabilities from pooled GLMM analyses with Huber/white
cluster robust sandwich variance estimation was used since GLMM analyses exhibited convergence
inconsistencies (19). Performance was assessed at an intended cutoff of 350 cells/mm3. A separate
performance assessment was done for the same test at 200 cells/mm3 to assess the ability of Visitect
CD4 to identify those with more advanced HIV disease.
Visitect CD4 test reproducibility (i.e., device variability) and interobserver reliability were also as-
sessed. One venous blood Visitect CD4 test was read by two independent health workers, who were
blinded to the test results of the other to assess interobserver reliability, using the  statistic, including
95% CI values. Test reproducibility was also assessed by comparing the diagnostic performance of the
three main operator cadres (nurses, counselor, and laboratory staff) of the Visitect CD4 tests on each
study participant using GLMM, as described above.
The reproducibility of the reference ﬂow cytometry CD4 level measurement was examined by
estimating the 95% limits of agreement between the two tests and also visually by plotting person-
speciﬁc differences in measurement versus the mean CD4 level (20). In addition, to further quantify the
level of agreement between ﬂow cytometry CD4 measurements, variance components modeling of ﬂow
cytometry CD4 measurements and derivations based on within-subject mean bias and variance in CD4
measurement (21) were undertaken to provide both intraclass correlation coefﬁcient (ICC) and coefﬁcient
of variation (CV) estimates, respectively.
All analyses were undertaken using Stata version 14.2, and statistical signiﬁcance was assessed at the
5% level.
This study was approved by the University of Witwatersrand Human Research Ethics Committee
(medical; protocol reference M140534) and the Alfred Hospital Ethics Committee, Australia (project
256/14).
RESULTS
Participant characteristics. At Rahima Moosa Mother and Child Hospital, 156
patients were enrolled between March and June 2017. Participants were a median
33 years of age (interquartile range [IQR], 28.5 to 36; range, 19 to 46). At the time of
testing, 5.8, 26.3, and 66.0% of women were in their ﬁrst, second, or third trimester of
pregnancy, respectively, and less than half (42.3%) had completed four or more
antenatal care visits. The large majority of the women (98.7%) were receiving antiret-
roviral therapy. One in ten women (16/156) reported to have missed or delayed an
Luchters et al. Journal of Clinical Microbiology
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antenatal visit because of costs of these visits. The women reported spending a median
$1.9 per visit for transport and incidentals to the clinic (IQR, $1.5 to $2.3; range, $0.7 to
$11.4).
Reference test results. Two participants had only a single reference test result, and
one had no reference result (see Fig. 3 and 4). Six participants (3.9%) had discrepant
reference CD4 cell counts of around 350 cells/mm3 cutoff (i.e., reference tests above
and below the 350-cells/mm3 cutoff). The remaining 147 participants with duplicate
reference test results had a mean CD4 cell count of 478 cells/mm3 (standard deviations
[SD]  215), with 39 women (26.5%) having a CD4 cell count of 350 cells/mm3 and
108 (73.5%) having 350 cells/mm3 (Fig. 2).
The mean difference (or bias) between reference CD4 test assessments from 153
participants with duplicate assessments was –6.9 cells/mm3 (SD 44.5; Fig. 2). The 95%
limits of agreement between the two assessments ranged from –94.2 to 80.3 cells/mm3.
The intraclass correlation coefﬁcient for participant ﬂow cytometry CD4 measurements
was high (ICC 0.98, 95% CI 0.97 to 0.98), and the coefﬁcient of variation was
approximately 15% (CV 14.7%, 95% CI 12.9 to 16.5%).
Visitect CD4 ﬁeld performance and diagnostic accuracy. A total of 624 Visitect
CD4 tests were performed (three venous and one ﬁnger prick). Visitect CD4 perfor-
mance is visually presented in ﬂow diagrams in accordance with STARD guidelines (16)
separately for the 468 tests on venous EDTA samples (Fig. 3) and 156 tests on
ﬁnger-prick samples (Fig. 4).
Of 624 Visitect CD4 tests, 28 (4.5%) were inconclusive: 22 inconclusive results of 468
venous samples (5 invalid results and 17 operator failures) and 6 inconclusive results of
156 ﬁnger-prick samples (3 invalid results and 3 operator failures). Operator failures
involved tests that were not performed according to the test protocol, as self-reported
by the respective operator, and were all read more than 45 min after test commence-
ment.
Our GLMM performed on the 147 women with 539 conclusive reference tests and
conclusive Visitect CD4 tests (of 561 tests, there were 22 tests performed by other
operators and excluded from GLMM) showed a statistically signiﬁcant difference in the
diagnostic performance of the Visitect CD4 when performed on venous blood com-
pared to ﬁnger-prick blood [LR 2(2) 14.32, P 0.001; Table 1, model C]. Performance
FIG 2 Difference in ﬂow cytometry CD4 measurements across the two test occasions by mean CD4 level
among 153 participants.
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on venous blood at CD4 350 mm3 cutoff showed a sensitivity of 81.7% (95% CI 72.3
to 91.1) and speciﬁcity of 82.6% (95% CI 77.1 to 88.1), whereas the diagnostic
performance on ﬁnger-prick blood showed a sensitivity of 60.7% (95% CI 45.0 to 76.3)
and speciﬁcity of 89.5% (95% CI 83.2 to 95.8).
The Visitect CD4 test showed higher sensitivity in diagnosing those with more
advanced HIV immune suppression (Table 2). On venous blood, diagnostic performance
of Visitect CD4 for CD4 200 cells/mm3 showed a sensitivity of 91.1% (95% CI 80.4
to 100) and a speciﬁcity of 73.1% (95% CI 66.9 to 79.3). On ﬁnger-prick blood, the
sensitivity was 80.2% (95% CI 62.0 to 98.3) and the speciﬁcity was 83.4% (95%
CI 76.8 to 90.1; Table 2, model C), and values differed signiﬁcantly from venous blood
performance [LR 2(2)  12.31, P 0.002].
Visitect CD4 test reproducibility. Importantly, there was no difference detected in
the diagnostic performance of the Visitect CD4 between the laboratory technologist
and counselor in the clinical lab and the nurse testing at the point of care; LR 2(4) 
7.48, P 0.113; Table 1, model B). For the nurse, who was the only health worker
performing the test at the point of care and also on ﬁnger-prick blood, the sensitivity
was 70.5% (95% CI 58.3 to 82.7), and the speciﬁcity was 86.7% (95% CI 81.2 to
92.2), whereas the performance by the lab tech and counselor showed a sensitivity of
80.6% (95% CI 67.9 to 93.3)/speciﬁcity of 84.8% (95% CI 77.8 to 91.8) and a
sensitivity of 82.4% (95% CI 70.1 to 94.8)/speciﬁcity of 79.7% (95% CI 72.0 to 87.4),
respectively. A post hoc comparison of the effect difference in diagnostic accuracy
between testing in the clinic laboratory or at the point-of-care showed no statistically
FIG 3 Flow diagram of 468 Visitect CD4 tests performed on 156 venous EDTA samples (pooled analysis from all operators) and reported
in accordance with the STARD statement (16).
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signiﬁcant effect: Wald 2(1)  3.70 and P 0.108 (that is, Bonferroni adjusted –pbi 
kpi, where k is the number of comparisons undertaken; in this instance k  2).
Interobserver reliability between the ﬁrst readout and second readout of the same
test strip by two health workers showed excellent agreement ( statistic  100%).
DISCUSSION
In the era of test-and-treat for all HIV-infected individuals, but with more than a third
of people starting ART with advanced HIV disease (22), the speciﬁcations and require-
ments of a true rapid point-of-care CD4 test may need to be further developed and
deﬁned (1, 2). An ideal point-of-care CD4 test should be semiquantitative, easily
performed by nontechnical and/or nonspecialized health care staff at the bedside, and
able to accurately guide decisions related to clinical management and treatment
initiation (1, 2).
Our study is the ﬁrst study to describe the ﬁeld performance and diagnostic
accuracy of the new single-use instrument-free low-cost point-of-care Visitect CD4 test
when performed by different health worker cadres. The device showed acceptable
pooled sensitivity (81.7%) and speciﬁcity (82.6%) at diagnosing CD4 350 cells/mm3
on venous samples of HIV-infected pregnant women in a public hospital in South
Africa, and performance did not differ whether performed by nurses, counselors, or
laboratory technicians.
If used for the initiation of co-trimoxazole prophylaxis and preemptive treatment or
prioritization of ART for those with a CD4 count of 350 cells/mm3, the observed
sensitivity of Visitect CD4 on venous samples would mean that a ﬁfth of participants
FIG 4 Flow diagram of 156 Visitect CD4 tests done on 156 ﬁnger-prick EDTA samples performed by the nurse and reported in accordance
with the STARD statement (16).
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with CD4 350 cells/mm3 were not identiﬁed. Performance, however, improved sig-
niﬁcantly for those with the highest need of ART and co-trimoxazole initiation (23, 24),
where the Visitect CD4 correctly identiﬁed more than 90% of those with CD4 200
cells/mm3, although the number of participants was small. These results are also
encouraging in that most individuals falsely categorized as having a CD4 count of350
cells/mm3 had a CD4 count close to 350 cells/mm3, which reduces the potentially
harmful impact of misclassiﬁcation, particularly in the era of “treat all.”
The Visitect CD4 performance using ﬁnger-prick blood samples proved suboptimal
(61% sensitivity and 90% speciﬁcity) and differed signiﬁcantly from performance on
venous blood. Some (9, 15, 25), though not all (26, 27), studies have alluded to
suboptimal performance of CD4 testing using capillary blood. Some staff reported
difﬁculties with obtaining adequate samples from ﬁnger pricks and differences in
sample collection devices (capillary tube for ﬁnger-prick versus micropipette for venous
blood) may explain these differences. Given that the nurse performed both a ﬁnger
prick-based test and a venous blood-based test at the point of care, it is unlikely that
the lower performance of the test with ﬁnger-prick blood is due to operator error or to
it being relatively more difﬁcult to follow test procedures at the bedside than in the
laboratory.
Importantly, test performance on venous blood did not alter when conducted by
TABLE 1 Diagnostic accuracy of Visitect CD4 at a cutoff of  350 cells/mm3 from GLMMa
Factor
Value (95% CI)
Model A Model B
Sens Spec PPV NPV Sens Spec PPV NPV
Overall 75.9 (66.1–85.8) 84.3 (79.3–89.3) 64.7 (53.1–76.3) 90.5 (85.7–95.3)
Operator
Lab tech 80.6 (67.9–93.3) 84.8 (77.8–91.8) 66.7 (52.8–80.5) 92.4 (87.0–97.8)
Nurse 70.5 (58.3–82.7) 86.7 (81.2–92.2) 67.7 (54.3–80.8) 88.4 (82.5–94.3)
Counselor 82.4 (70.1–94.8) 79.7 (72.0–87.4) 58.8 (45.3–72.4) 93.1 (87.8–98.4)
Sample type
Venous
Finger-prick
aGLMM generalized through use of a logit link function and binomial distribution with a random intercept for test participant (n  147). Sens, test sensitivity; Spec,
test speciﬁcity; PPV, positive predictive value; NPV, negative predictive value; ICC, intraclass correlation coefﬁcient from random intercept GLMM; model A,
unadjusted; model B, operator by test interaction and main effect (not shown); model C, Blood sample type by test interaction and main effect (not shown). PPV and
NPV estimates were determined from ordinary logit GLM with cluster robust standard errors. GLMM analyses would not converge reliably.
bLikelihood ratio (LR) tests comparing nested less-constrained models (B and C) with model A.
TABLE 2 Diagnostic accuracy of Visitect CD4 at a cutoff of  200 cells/mm3 from GLMMa
Factor
Value (95% CI)
Model A Model B
Sens Spec PPV NPV Sens Spec PPV NPV
Overall 87.9 (76.3–99.5) 75.5 (69.9–81.2) 30.0 (17.9–42.1) 98.4 (97.2–99.7)
Operator
Lab tech 85.4 (69.0–100) 74.4 (66.8–82.1) 31.1 (17.5–44.7) 97.8 (94.8–100)
Nurse 88.0 (74.8–100) 79.1 (73.1–85.1) 35.1 (20.9–49.3) 98.4 (96.6–100)
Counselor 90.4 (75.4–100) 70.3 (62.3–78.3) 27.5 (15.1–39.7) 98.9 (96.7–100)
Sample type
Venous
Finger prick
aGLMM generalized through use of a logit link function and binomial distribution with a random intercept for test participant (n  147). PPV and NPV estimates were
determined from ordinary logit GLM with cluster robust standard errors. GLMM analyses would not converge reliably. Sens, test sensitivity; Spec, test speciﬁcity; PPV,
positive predictive value; NPV, negative predictive value; ICC, intraclass correlation coefﬁcient from random intercept GLMM; model A, unadjusted; model B, operator
by test interaction and main effect (not shown); model C  Blood sample type by test interaction and main effect (not shown).
bLikelihood ratio (LR) tests comparing nested less-constrained models (B and C) with model A.
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different cadres of health care workers. In our study, conduct of the test by an
experienced laboratory technologist was no different from the diagnostic performance
of a counselor and a nurse with the same device-speciﬁc training. Similar ﬁndings were
observed in other point-of-care CD4 tests, such as the Pima (28). The somewhat lower
sensitivity obtained by the nurse can likely be explained by the fact that the nurse was
the only operator doing the tests on the ﬁnger-prick samples which we show in model
C to have inferior performance.
Before study commencement, operators received an estimated 15 h of training and
a 2.5-month practice period, during which operators conducted multiple tests. This
proved sufﬁcient, but such training might not be reﬂective of real-life training oppor-
tunities, and minimum training requirements need to be established.
In general, operators liked the simplicity and immediate availability of test results
(40 min). A more detailed qualitative exploration of health worker perspectives and the
feasibility and acceptability is presented separately (unpublished data). Immediate
availability of CD4 test results has important advantages for results communication and
enabling urgent linkage to care and ART initiation for those most in need. Point-of-care
CD4 testing has been found to be effective in improving patient linkage to care, patient
retention in care and timeliness of ART initiation (14, 29). These positive impacts would
lead to improvements in treatment effects, the quality of care, and the ultimately
quality of life of HIV-infected individuals along the HIV treatment cascade.
All current commercially available point-of-care CD4 testing technologies have one
common pitfall: they do require power supply and some level of equipment to perform
the test. Such equipment requires initial investments and regular maintenance by a
TABLE 1 (Continued)
Value (95% CI)
Inferenceb and heterogeneityModel C
Sens Spec PPV NPV LR (2) P ICC
0.57
2(4)  7.48 0.113 0.58
2(2)  14.32 0.001 0.61
81.7 (72.3–91.1) 82.6 (77.1–88.1) 63.0 (51.3–74.7) 92.6 (88.0–97.1)
60.7 (45.0–76.3) 89.5 (83.2–95.8) 71.9 (56.2–87.5) 85.0 (78.0–92.0)
TABLE 2 (Continued)
Value (95% CI)
Inferenceb and heterogeneityModel C
Sens Spec PPV NPV LR (2) P ICC
0.68
2(4)  6.65 0.156 0.69
2(2)  12.31 0.002 0.70
91.1 (80.4–100) 73.1 (66.9–79.3) 28.9 (16.9–40.8) 98.9 (97.3–100)
80.2 (62.0–98.3) 83.4 (76.8–90.1) 34.2 (19.1–49.3) 97.1 (93.9–100)
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qualiﬁed technician. Recent research has shown that inadequate maintenance of test
machines, equipment breakdown, commodity stock-out, and lack of appropriate train-
ing for health care staff may contribute to unacceptable failure rates, increased ma-
chine downtime, and delays in turnaround time of CD4 test results (15, 30). Studies with
Pima have reported a wide range of failure rates: with capillary blood this ranged from
2 to 23.3%, and with venous blood in various clinical settings it ranged from 4.8 to
15.2% (15). As a result, there remain serious limitations accessing CD4 testing facilities,
particularly in the more remote and rural areas, or in places with lower burden of
HIV-infection where investments in a CD4 machine might not be warranted.
A single-use, instrument-free, true point-of-care CD4 test that can perform well when
conducted by different health worker cadres and at the point of care, such as the Visitect
CD4, could signiﬁcantly increase patient access to CD4 testing services and respond to the
WHO-identiﬁed research priority for simpliﬁed CD4 cell count testing (31).
Limitations. Although use of the mean of the two ﬂow cytometry tests may counter
the lack of reliability or repeatability of these tests and better represent the “true” CD4
count of a participant, there are challenges in deﬁning the reference level for a CD4
count. Clearly, inaccuracies introduced by the reference test reduce the sensitivity and
speciﬁcity of the candidate tests.
In this clinical setting, nearly half the enrolled participants (47%, 72/153) had an
average CD4 cell count between 200 and 500 cells/mm3, thereby challenging the
diagnostic accuracy of any device. Even the gold standard reference ﬂow cytometry
had difﬁculties in six participants, who had discordant results on their duplicate testing
of one sample around the cutoff.
The Visitect CD4 test is currently designed to detect patients with a CD4 cell count
of350 cells/mm3. The development of a Visitect CD4 with lower cutoffs of 100 and/or
200 cells/mm3 could be a useful addition to further support evidence-based clinical
management.
Although an important target group, the fact that our study only involved pregnant
women and a relatively small number of subjects limits the generalizability of our
ﬁndings. Since pregnancy is associated with a multitude of biological and hormonal
changes, it might inﬂuence the performance of the test, and this highlights the need
for performance data among other patient groups.
Our study was conducted in a referral hospital by well-trained staff with previous
experience using lateral ﬂow tests. This might not be a good reﬂection of performance
among health care workers in more remote areas with potentially lower educational
background and less training.
Conclusions. CD4 measurement has an important role to play in assessing baseline
risk of disease progression, particularly for individuals presenting with advanced dis-
ease, decisions regarding starting and stopping prophylaxis for opportunistic infec-
tions, and prioritization decisions regarding ART initiation in settings where universal
treatment is not yet possible. Consistently good performance of the Visitect CD4 on
venous blood with different operators, in combination with the fact that no electricity
and no instrument is required for conducting the test, shows the potential of this
device for decentralization of CD4 testing services in the most resource-constrained
settings. Further research is needed to make any conclusions regarding the appropri-
ateness of using ﬁnger-prick for CD4 testing. The considerable ﬁnancial and clinical
beneﬁts associated with obtaining a test result at the point of care may outweigh the
risks associated with a false-negative result.
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